UTMD
Utah Medical Products, Inc.58.43
+0.94+1.64%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
187.31MP/E (TTM)
16.51Basic EPS (TTM)
3.54Dividend Yield
0.02%Recent Filings
10-Q
8-K
8-K
Q3 revenues dip 2% on cancellations
Utah Medical Products reported Q3 2025 revenues down 2% to $9.8M and 9M sales off 7% to $29.5M, hit hard by a China distributor's cancellation of non-cancellable orders, costing $581K in revenue and a $395K bad debt reserve. Operating income plunged 22% in Q3 amid lower absorption and higher expenses, yet share repurchases cushioned EPS decline to 20%. Tariffs jacked up costs; full-year sales now eyed 7% below 2024.
10-Q
Q2 FY2025 results
Utah Medical Products posted Q2 FY2025 sales of $9.95M, down 4.3% y/y but up 6.7% q/q (derived), as PendoTECH OEM demand eased while direct U.S. sales climbed 10% y/y. Gross margins slipped to 56.2% from 60.1% y/y, hit by Ireland's product mix and lower volumes, yet operating income held at $3.20M (32.1% margin) thanks to $355K less litigation spend. Diluted EPS of $0.94 edged down 4.0% y/y, cushioned by share buybacks shrinking diluted shares to 3.25M from 3.53M; YTD EPS of $1.86 reconciles fully with no anti-dilution. Cash stayed rock-solid at $82.2M with zero debt, funding $6.7M repurchases and $2.0M dividends amid $7.3M operating cash flow. Non-GAAP EBITDA not disclosed in the 10-Q. Shares repurchased. Tariff threats loom over OUS distributor orders.
8-K
Q2 revenues dip 4.3%
Utah Medical Products reported Q2 2025 revenues of $9.953 million, down 4.3% from $10.4 million in Q2 2024, driven by a 61.7% drop in sales to OEM customer PendoTECH, though offset by 10% growth in direct domestic device sales and 8% in U.S. Filshie Clip System. Gross margins slipped to 56.2% from 60.1% due to unfavorable mix in Ireland operations and lower volumes absorbing fixed costs, while operating income fell 7.1% to $3.196 million amid $355 lower litigation expenses. Net income declined 11.7% to $3.048 million, with EPS at $0.939 after buybacks reduced shares. Balance sheet stays debt-free with $82.2 million in cash; PendoTECH sales expected $2 million lower for full-year 2025.
IPO
Website
Employees
Sector
Industry
BFLY
Butterfly Network, Inc.
3.34+0.12
CNMD
CONMED Corporation
39.20-1.12
ICUI
ICU Medical, Inc.
147.07-0.96
MASI
Masimo Corporation
134.52-2.88
MDT
Medtronic plc.
97.72-0.85
MHUA
Meihua International Medical Te
7.61-6.41
MMSI
Merit Medical Systems, Inc.
86.85+0.44
RMD
ResMed Inc.
247.34-5.73
UEEC
United Health Products, Inc.
0.06+0.00
UFPT
UFP Technologies, Inc.
217.74-0.08